Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1:13:901365.
doi: 10.3389/fimmu.2022.901365. eCollection 2022.

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era

Suheil Albert Atallah-Yunes  1 , Michael J Robertson  1 , Utpal P Davé  1   2 , Paola Ghione  3 , Fabiana Perna  1
Affiliations
Review

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era

Suheil Albert Atallah-Yunes et al. Front Immunol. .

Abstract

Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50% of patients. However, there remains an unmet need for developing novel therapies to improve clinical outcomes of patients not responding or relapsing after CAR T cell therapies. Lack of suitable immunotherapeutic targets and disease heterogeneity represent the foremost challenges in this emerging field. In this review, we discuss the recently approved and emerging novel immunotherapies for patients with R/R DLBCL in the post-CAR T era and the cell surface targets currently used.

Keywords: chimeric antigen receptor T-cell therapy; diffuse large B-cell lymphoma; discovery; high-risk; immunotherapy; target.

PubMed Disclaimer

Conflict of interest statement

PG participated in advisory boards for Astra Zeneca, Daiichi Sanyo, Secura Bio and Kyowa Hakko Kirin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Liu Y, Barta SK. Diffuse Large B-Cell Lymphoma: 2019 Update on Diagnosis, Risk Stratification, and Treatment. Am J Hematol (2019) 94(5):604–16. doi: 10.1002/ajh.25460 - DOI - PubMed
    1. Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management. Am J Hematol (2021) 96(5):617–29. doi: 10.1002/ajh.26151 - DOI - PMC - PubMed
    1. Sawalha Y. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. J Pers Med (2021) 11(12):1345. - PMC - PubMed
    1. Sarkozy C, Sehn LHJAL. New Drugs for the Management of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Annals Lymphoma (2019) 3(10).
    1. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. . Gene-Expression Profiling and Not Immunophenotypic Algorithms Predicts Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Blood (2011) 117(18):4836–43. - PubMed

Publication types

LinkOut - more resources